PRA International Expands Operations in Mexico

Friday, December 12, 2008 General News J E 4
RALEIGH, N.C., Dec. 11 PRA International, a leadingClinical Research Organization, announces the opening of a new office inMexico City, Mexico. With years of long-standing South American operations,PRA entered the Mexico market in 2005. The region's existing base of clinicalsites with expertise in oncology, cardiovascular, CNS and infectious diseasesmatch favorably to PRA's therapeutic focus. The expansion is alsoadvantageous for PRA and its clients given Mexico's reliable regulatorytimelines and the ability to run placebo trials.

The new PRA location provides proximity to the large population center ofMexico City, easy access to the Ministry of Health, and the ability to overseetrials in Central America. The facility is home to more than 20 clinicalstaff, with room to expand to nearly 50 as trial volume in the regionincreases.

"We are pleased to formalize our operations in Mexico with a newfacility," commented Charles Schmidt, Senior Director of Operations for LatinAmerica. "Mexico is a country with a strong tradition in clinical trials. Itwill also help open the door for further expansion into Central America."

About PRA International

PRA International is a global Clinical Research Organization providingservices through all phases of clinical development. Although we specialize inOncology, CNS, Respiratory/Allergy, Cardiovascular and Infectious Diseases, weperform studies in all therapeutic areas. PRA has supported over 2,100clinical trials through its 32 global offices. PRA's therapeutic expertise,global reach and project experience, combined with extensive local knowledge,enable our project teams to deliver consistent and on time performance for ourclients.

To learn more about PRA International, please visit, email or call ourGlobal Headquarters at +1 (919) 786-8200.

SOURCE PRA International


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
AANMA Provides Commentary to FDA Advisory Committe...
Alimera Sciences Begins Pilot Study to Assess Safe...